Sun 2014.

Methods	Allocation: randomised. Blindness: not stated. Duration: 2 months.
Participants	Diagnosis: schizophrenia (CCMD‐3; PANSS > = 60). N = 108. Age: 18‐71 years. Sex: 51 men 43 women. History: average duration ill ˜ 6 years (SD ˜ 3). Inclusion criteria: not stated. Exclusion criteria: not stated.
Interventions	1. WDD (please see details in Table 5) + aripiprazole (dose stared from 5 mg/d, and increased individually, but did not exceed 30 mg/d.). N = 54. 2. Aripiprazole (dose stared from 5 mg/d, and increased individually, but did not exceed 30 mg/d). N = 54.
Outcomes	Global state: cure (binary PANSS scores ‐ reduced >75%, 50% to 74%, 25% to 49%, no effect ‐ <24%). Mental state: PANSS total. Adverse events: EPS, weight gain, constipation (dry stool) (TESS).
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "randomly divided in to intervention group and control …"
Allocation concealment (selection bias)	Unclear risk	Not stated.
Blinding of participants and personnel (performance bias) All outcomes	High risk	Not stated.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not stated.
Incomplete outcome data (attrition bias) All outcomes	Low risk	No missing outcome data.
Selective reporting (reporting bias)	Low risk	We were unable to locate original study protocol, however, all outcomes listed in the 'methods' section of the paper appear to have been measured and reported.
Other bias	Low risk	No obvious other bias.